Leerink Partners on AC Immune SA (ACIU): Lilly deal amendment is 'great news,' validates platform

April 7, 2026 2:44 PM

Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $9.00 price target on AC Immune SA (NASDAQ: ACIU)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found